| |
|
|
|
|
|
|
|||
|
Blood, Vol. 91 No. 8 (April 15), 1998:
pp. 2672-2678
By
From the Gladstone Institute of Virology and Immunology, San
Francisco, CA; and the Departments of Microbiology and Immunology and
Medicine, University of California, San Francisco, San Francisco,
CA.
It is still uncertain whether multilineage hematopoietic progenitor
cells are affected by human immunodeficiency virus-1 (HIV-1) infection
in vivo. The SCID-hu Thy/Liv model is permissive of long-term
multilineage human hematopoiesis, including T lymphopoiesis. This model
was used to investigate the effects of HIV-1 infection on early
hematopoietic progenitor function. We found that both lineage-restricted and multilineage hematopoietic progenitors were
depleted from grafts infected with either a molecular clone or a
primary isolate of HIV-1. Depletion of hematopoietic progenitors (including CD34+ cells, colony-forming units in
methylcellulose, and long-term culture-initiating cells) occurred
several days before the onset of thymocyte depletion, indicating that
the subsequent rapid decline in thymocyte numbers was due at least in
part to loss of thymocyte progenitors. HIV-1 proviral genomes were not
detected at high frequency in hematopoietic cells earlier than the
intrathymic T-progenitor cell stage, despite the depletion of
such cells in infected grafts. Proviral genomes were also not detected
in colonies derived from progenitor cells from infected grafts. These
data demonstrate that HIV-1 infection interrupts both
lineage-restricted and multilineage hematopoiesis in vivo and suggest
that depletion of early hematopoietic progenitor cells occurs in the
absence of direct viral infection.
ALL MODELS OF T-CELL depletion in human
immunodeficiency virus-1 (HIV-1) disease must invoke the failure of
hematopoietic organs to produce sufficient T cells to match the rate of
their destruction. Several lines of evidence implicate impaired
thymopoiesis as a causative factor in HIV-1-associated T-cell
depletion.1 HIV-1 infection of thymus in vivo has been
demonstrated.2 Intrathymic T progenitor cells have been
shown to be infectable by HIV-1 in vitro3,4 and in the
SCID-hu Thy/Liv model.5 The thymic pathology induced by
HIV-1 in the SCID-hu Thy/Liv model may be strain-dependent5-7 and includes both thymocyte depletion
and destruction of thymic epithelium.8 Prethymic progenitor
cells in bone marrow may also be infected and depleted by HIV-1,
although the frequency of HIV-1 infection of primitive progenitors
appears to be low.9-15 In particular, it is uncertain
whether HIV-1 effects on central hematopoietic organs such as bone
marrow or fetal liver are directly mediated by HIV-1 infection or are
the indirect result of altered levels of cytokines and trophic
factors.16,17 Animal model systems for HIV-1 infection may
assist in defining the pathology of HIV-1 for the design and testing of
therapies to reverse or prevent HIV-1-associated cytopenias. In
addition, the determination of the earliest stages in thymocyte
development affected by HIV-1 infection will be important for the
design of therapies to reconstitute immune function.
Among experimental models of HIV-1 infection, the SCID-hu Thy/Liv mouse
uniquely allows the study of human hematopoietic function at both the
thymic and prethymic stages.18 The conjoint organ formed by
transplantation of human fetal thymus and liver not only supports
long-term lymphopoiesis, but also maintains a self-replenishing pool of
primitive hematopoietic progenitor cells that show potential for
development into myeloid and erythroid lineages.
We have used this model to study the effects of HIV-1 infection on
early stages of hematopoiesis. Using both a molecular clone and primary
strains of HIV-1, we found that depletion of intrathymic T-progenitor
cells was a common feature of HIV-1 infection. Using both phenotypic
and functional analyses of earlier hematopoietic progenitor cells, we
found that HIV-1 infection resulted in depletion of both
lineage-restricted and multilineage progenitor cells. Depletion of
hematopoietic progenitor cells preceded the loss of
CD4+CD8+ and CD4+CD8 Animals and virus infection.
SCID-hu Thy/Liv mice were constructed as described18-20 and
maintained under specific pathogen-free barrier conditions. All animals
used in each experiment carried liver and thymus tissue from a single
fetal donor. Protocols for the use of fetal tissue were approved by the
UCSF Committee on Human Research, and protocols for the care and use of
SCID-hu mice were approved by the Committee on Animal Research. Thy/Liv
grafts were infected by intragraft injection of 2,000 TCID50 of each isolate or an equivalent volume of medium
for mock infection controls, as described.20
Virus stocks.
HIV-1 virus stocks were generated by low passage propagation of primary
strains (JD and PD) or molecular clones (NL4-3) in cultures of
phytohemagglutinin-activated peripheral blood mononuclear cells
(PBMCs).20 NL4-3 is an infectious molecular clone of
HIV-121 that has been maintained as a plasmid stock and not
extensively passaged in tissue culture. JD and PD are uncloned, early
passage, syncytium-inducing primary strains of HIV-1. Virus stocks were titrated on PBMC blasts and subjected to endpoint analysis as described.20
Thymocyte immunophenotyping and sorting.
Monoclonal antibodies were obtained from Becton Dickinson
Immunocytometry Systems (fluorescein isothiocyanate [FITC]-conjugated anti-CD4, phycoerythrin [PE]-conjugated anti-CD8, biotin-conjugated anti-CD3 and anti-CD8, PE-conjugated anti-CD34, and conjugated isotype
controls; Mountain View, CA) and from Caltag (TRI-COLOR-conjugated anti-CD3 and anti-CD8, TRI-COLOR-conjugated streptavidin, and conjugated isotype controls; Burlingame, CA). Cell sorting
was performed on a Becton Dickinson FACS Vantage fluorescence-activated cell sorter (FACS; Becton Dickinson Immunocytometry Systems, Mountain View, CA). Analysis was performed on either the FACS Vantage or on a
Becton Dickinson FACScan instrument with CellQuest
analysis software. Thymocytes were recovered from grafts by filtration through nylon mesh bags, and the number of total live cells recovered per graft was determined by hemocytometer counting and trypan blue dye
exclusion. For sorting of thymocyte subclasses, freshly isolated
thymocytes were surface stained with FITC-conjugated anti-CD4,
PE-conjugated anti-CD8, and TRI-COLOR-conjugated anti-CD3. Percentages of single-positive CD4 and CD8 thymocytes
(CD3+CD4+CD8 Progenitor cell assays.
Progenitor cells were enriched from bulk thymocytes by negative
selection with biotinylated anti-CD3 and anti-CD8 monoclonals and
streptavidin-coated magnetic beads (Dynal, Lake Success,
NY) and subsequently divided into aliquots for CD34 staining or plating into methylcellulose assays (to measure colony-forming
units-cells [CFU-C]) or long-term bone marrow assays (to measure
long-term culture-initiating cells [LTC-IC]). The efficiency of bead
depletion was assessed by reanalysis using streptavidin-TRI-COLOR.
CD34+ progenitor cells were enumerated by surface staining
the CD3- and CD8-depleted thymocytes with PE-conjugated anti-CD34
antibody. A total of 100,000 to 500,000 Thy/Liv cells depleted of CD3-
and/or CD8-thymocytes were added to methylcellulose
cultures (Stem Cell Technologies, Vancouver, British
Columbia, Canada) supplemented with 100 ng/mL stem cell factor (SCF)
and granulocyte-macrophage colony-stimulating factor (GM-CSF), 10 ng/mL
interleukin-3 (IL-3) and IL-6, and 2 U/mL erythropoietin
(EPO; all cytokines were obtained from R&D
Systems, Minneapolis, MN). Triplicate plates were scored for
colony-forming units-granulocyte-macrophage (CFU-GM), burst-forming units-erythroid (BFU-E), and colony-forming
units-granulocyte, erythroid, monocyte, megakaryocyte (CFU-GEMM)
after 14 days. LTC-IC were assayed by limiting dilution analysis
of CD3- and CD8-depleted cells as previously described,22
except that cells were grown on irradiated fetal bone marrow stromal
cultures. Cultures were grown for 5 to 6 weeks in the presence of IL-3,
IL-6, and SCF and scored for growth-positive wells. Total CFU-C and
LTC-IC per graft were calculated as total colonies scored in
methylcellulose assay or long-term bone marrow culture, respectively,
divided by the fraction of postdepletion cells plated in each assay,
divided by the fraction of total cells set aside for bead depletion.
The total number of CD34+ cells per graft was calculated as
the percentage of bead-depleted cells positive for CD34 staining,
multiplied by the number of cells recovered after bead depletion,
divided by the fraction of total cells set aside for bead depletion.
Polymerase chain reaction (PCR) amplification of HIV-1 proviral
sequence.
Cells recovered from Thy/Liv grafts were stained with monoclonal
antibodies to CD3, CD4, CD8, and/or CD34. Live cells were defined by forward and side scatter, and 2,000 cells of each subset (total thymocytes, CD34+,
CD3+CD4+CD8 Time-dependent depletion of mature and immature thymocytes by HIV-1.
Previous work with the SCID-hu Thy/Liv model demonstrated a
time-dependent depletion of
CD3+CD4+CD8+ and
CD3+CD4+CD8
Early depletion of hematopoietic progenitor cells by HIV-1.
The finding that multiple HIV-1 strains depleted thymic progenitors
prompted us to determine whether earlier hematopoietic progenitor cells
were also affected by HIV-1 infection in the SCID-hu Thy/Liv mouse. We
therefore measured the clonogenic capacity of multilineage and
lineage-restricted hematopoietic progenitor cells from grafts infected
either with NL4-3 or with medium. At early and late time points after
infection, aliquots of harvested thymocytes were subjected to
quantitative immunophenotyping with antibodies to CD3, CD8, and CD4 or
depleted of mature cells with antibodies to CD3 and CD8 and then either
assayed for expression of CD34 or for hematopoietic clonogenic capacity
in methylcellulose or in long-term bone marrow cultures. At days 4 to
11 after infection, significantly fewer CD34+ cells
remained in grafts infected with NL4-3 compared with controls (Fig
2). At this early time point there was no
depletion of lineage-restricted progenitor cell activity as measured by
methylcellulose colony-forming units (CFU-C) or of total thymocytes. At
days 12 to 14 after infection, both CD34+ cells and
lineage-restricted progenitors were diminished relative to controls,
and the degree of depletion exceeded that of total thymocytes
(P < .05). By days 17 to 21 after infection, all
hematopoietic elements in the Thy/Liv grafts, including total
thymocytes, CFU-Cs, and CD34+ cells, were severely
depleted. Thus, depletion of both functional (lineage-restricted) and
phenotypic progenitors preceded the rapid decrease in total thymocyte
numbers seen between day 11 and 21 after infection in this model.
Progenitor depletion is a property shared by a primary HIV-1 strain
and a molecular clone.
To determine whether depletion of hematopoietic progenitors was a
property shared by primary HIV-1 strains, SCID-hu Thy/Liv grafts were
infected in parallel with NL4-3 or the primary isolate JD (Fig
5). At late (day
28) time points after infection, each virus was found to deplete both
total thymocytes and CD34+ progenitor cells as well as
colony-forming cells. However, at day 12 after infection, grafts
infected with either virus showed normal numbers of total thymocytes
but decreased numbers of CFU-C and CD34+ progenitor cells.
These data suggest that the ability of HIV-1 to impair thymopoiesis
through progenitor depletion is shared by a primary HIV-1 strain and by
the molecular clone NL4-3.
HIV-1 proviral DNA accumulates in intrathymic T-cell progenitors but
not in earlier progenitors.
Because HIV-1 infection may diminish hematopoietic progenitor capacity
either by direct means (eg, lytic viral infection of progenitor cells)
or by indirect means (eg, upregulation of hematosuppressive cytokines
or disruption of stromal cell support), we evaluated the possibility
that hematopoietic progenitor cells in the SCID-hu Thy/Liv graft were
infected by HIV-1. First, DNA from colonies generated in
methylcellulose culture was tested for the presence of proviral HIV-1
DNA using the PCR. Between 5 and 28 days after infection of grafts with
NL4-3 or JD, only 4 of 1,293 colonies tested were positive for gag
sequences (Table 1). This rate of PCR
signal positivity is no higher than what might have arisen from
carryover DNA in the culture, suggesting either that progenitor cells
are uninfected by HIV-1 or that infected progenitor cells fail to
generate colonies in methylcellulose assays. Secondly, sort-purified
subpopulations of cells within the Thy/Liv implant were subjected to a
quantitative, endpoint-dilution PCR analysis for the presence of HIV-1
proviral genomes. Among various potential target cells, intrathymic
T-progenitor cells consistently harbored the highest frequency of HIV-1
genomes (Table 2). Intermediate levels of
infection were observed in more mature
CD3+CD4+CD8
HIV-induced impairment of hematopoietic progenitor function has been
studied by a variety of in vitro methods with equivocal results.16,17,26 Major limitations of these methods include lack of control of maturation in tissue culture, nonphysiological development, and incomplete representation of stromal elements that may
participate in HIV-1-induced pathology. In this study, we have
addressed the effects of HIV-1 infection with an in vivo model, the
SCID-hu Thy/Liv mouse, which encompasses the hematopoietic function of
both thymus and fetal liver. We were thus able to observe effects on
thymopoiesis and multilineage hematopoiesis simultaneously and to
measure effects of HIV-1 infection on each. This model has been shown
to recapitulate primary HIV-1 strain-specific pathology seen in
vivo.6-8 With it, we have shown that HIV-1 infection
impairs hematopoietic progenitor capacity in vivo at a stage as early
as the multilineage progenitor population. In a kinetic analysis of
thymocyte depletion, the impairment of lineage-restricted and
multilineage progenitors was found to precede by several days the rapid
decline in more mature thymocyte numbers. This observation was valid
for both a molecular clone of HIV-1 and a primary strain, suggesting
that hematopoietic progenitor cell depletion may be a common feature of
HIV-1 pathology. We conclude that the rapid decline in thymocyte
numbers seen in the SCID-hu model is likely to be the consequence of
concurrent depletion of both thymocyte progenitor cells and more mature
CD4+ thymocytes.
Submitted December 1, 1997;
accepted January 12, 1998.
The authors thank Robert M. Grant, MD, MPH, for advice on statistical
analysis of data in this report.
1.
McCune JM:
Thymic function in HIV-1 disease.
Semin Immunol
9:397,
1997[Medline]
[Order article via Infotrieve]
2.
Calabro ML,
Zanotto C,
Calderazzo F,
Crivellaro C,
del Mistro A,
de Rossi A,
Chieco-Bianchi L:
HIV-1 infection of the thymus: Evidence for a cytopathic and thymotropic viral variant in vivo.
AIDS Res Hum Retroviruses
11:11,
1995[Medline]
[Order article via Infotrieve]
3.
Schnittman SM,
Denning SM,
Greenhouse JJ,
Justement JS,
Baseler M,
Kurtzberg J,
Haynes BF,
Fauci AS:
Evidence for susceptibility of intrathymic T-cell precursors and their progeny carrying T-cell antigen receptor phenotypes TCR alpha/beta+ and TCR gamma/delta+ to human immunodeficiency virus infection: A mechanism for CD4+ (T4) lymphocyte depletion.
Proc Natl Acad Sci USA
87:7727,
1990
4.
Valentin H,
Nugeyre MT,
Vuillier F,
Boumsell L,
Schmid M,
Barre-Sinoussi F,
Pereira RA:
Two subpopulations of human triple-negative thymic cells are susceptible to infection by human immunodeficiency virus type 1 in vitro.
J Virol
68:3041,
1994
5.
Su L,
Kaneshima H,
Bonyhadi M,
Salimi S,
Kraft D,
Rabin L,
McCune JM:
HIV-1 induced thymocyte depletion is associated with indirect cytopathicity and infection of progenitor cells in vivo.
Immunity
2:25,
1995[Medline]
[Order article via Infotrieve]
6.
Aldrovandi GM,
Feuer G,
Gao L,
Jamieson B,
Kristeva M,
Chen ISY,
Zack JA:
The SCID-hu mouse as a model for HIV infection.
Nature
363:732,
1993[Medline]
[Order article via Infotrieve]
7.
Bonyhadi ML,
Rabin L,
Salimi S,
Brown DA,
Kosek J,
McCune JM,
Kaneshima H:
HIV induces thymus depletion in vivo.
Nature
363:728,
1993[Medline]
[Order article via Infotrieve]
8.
Stanley SK,
McCune JM,
Kaneshima H,
Justement JS,
Sullivan M,
Boone E,
Baselar M,
Adelsberger J,
Bonyhadi M,
Orenstein J,
Fox CH,
Fauci AS:
Human immunodeficiency virus infection of the human thymus and disruption of the thymic microenvironment in the SCID-hu mouse.
J Exp Med
178:1151,
1993
9.
Folks TM,
Kessler SW,
Orenstein JM,
Justement JS,
Jaffe ES,
Fauci AS:
Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow.
Science
242:919,
1988
10.
Davis BR,
Schwartz DH,
Marx JC,
Johnson CE,
Barry JM,
Lyding J,
Merigan TC,
Zander A:
Absent or rare human immunodeficiency virus infection of bone marrow stem/progenitor cells in vivo.
J Virol
65:1985,
1991
11.
Kitano K,
Abboud CN,
Ryan DH:
Macrophage-active colony-stimulating factors enhance human immunodeficiency virus type 1 infection in bone marrow stem cells.
Blood
77:1699,
1991
12.
Kaushal S,
La Russa VF,
Gartner S,
Kessler S,
Perfetto S,
Yu Z,
Ritchey DW,
Xu J,
Perera P,
Kim J,
Reid T,
Mayers DL,
St. Louis D,
Mosca JD:
Exposure of human CD34+ cells to human immunodeficiency virus type 1 does not influence their expansion and proliferation of hematopoietic progenitors in vitro.
Blood
88:130,
1996
13.
Neal TF,
Holland HK,
Baum CM,
Villinger F,
Ansari AA,
Saral R,
Wingard JR,
Fleming WH:
CD34+ progenitor cells from asymptomatic patients are not a major reservoir for human immunodeficiency virus-1.
Blood
86:1749,
1995
14.
Stanley SK,
Kessler SW,
Justement JS,
Schnittman SM,
Greenhouse JJ,
Brown CC,
Musongela L,
Musey K,
Kapita B,
Fauci AS:
CD34+ bone marrow cells are infected with HIV in a subset of seropositive individuals.
J Immunol
149:689,
1992[Abstract]
15.
Steinberg HN,
Crumpacker CS,
Chatis PA:
In vitro suppression of normal human bone marrow progenitor cells by human immunodeficiency virus.
J Virol
65:1765,
1991
16. McCune JM, Kaneshima H: The hematopathology of HIV-1 disease:
Experimental analysis in vivo, in Roncarolo M-G, Peault B, Namikawa R
(eds): Human Hematopoiesis in SCID Mice, Medical Intelligence Unit.
Austin, TX, Landes, 1995, p 129
17.
Zauli G,
Capitani S:
HIV-1-related mechanisms of suppression of CD34+ hematopoietic progenitors.
Pathobiology
64:53,
1996[Medline]
[Order article via Infotrieve]
18.
Namikawa R,
Weilbaecher KN,
Kaneshima H,
Yee EJ,
McCune JM:
Long-term human hematopoiesis in the SCID-hu mouse.
J Exp Med
172:1055,
1990
19.
McCune JM,
Namikawa R,
Kaneshima H,
Shultz LD,
Lieberman M,
Weissman IL:
The SCID-hu mouse: Murine model for the analysis of human hematolymphoid differentiation and function.
Science
241:1632,
1988
20.
Rabin L,
Hincenbergs M,
Moreno MB,
Warren S,
Linquist V,
Datema R,
Charpiot B,
Seifert J,
Kaneshima H,
McCune JM:
Use of a standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds.
Antimicrob Agents Chemother
40:755,
1996[Abstract]
21.
Adachi A,
Gendelman HE,
Koenig S,
Folks T,
Willey R,
Rabson A,
Martin MA:
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.
J Virol
59:284,
1986
22.
DiGiusto D,
Chen S,
Combs J,
Webb S,
Namikawa R,
Tsukamoto A,
Chen BP,
Galy AHM:
Human fetal bone marrow early progenitors for T, B and myeloid cells are found exclusively in the population expressing high levels of CD34.
Blood
84:421,
1994
23.
McCune JM,
Namikawa R,
Shih C-C,
Rabin L,
Kaneshima H:
Suppression of HIV infection in AZT-treated SCID-hu mice.
Science
247:564,
1990
24. Lenette EH: General principles underlying laboratory diagnosis
of virus and rickettsial infections, in Lenette EH, Schmidt NJ (eds):
Diagnostic Procedures of Virus and Rickettsial Disease. New York, NY,
American Public Health Association, 1964, p 45
25.
Kaneshima H,
Su L,
Bonyhadi M,
Conner R,
Ho D,
McCune JM:
Rapid-high, syncytium-inducing isolates of HIV directly induce cytopathicity in the human thymus of the SCID-hu mouse.
J Virol
68:8188,
1994
26.
Folks TM:
Human immunodeficiency virus in bone marrow: Still more questions than answers.
Blood
77:1625,
1991
27.
Jamieson B,
Uittenbogaart C,
Schmid I,
Zack J:
High viral burden and rapid CD4+ cell depletion in human immunodeficiency virus type 1-infected SCID-hu mice suggest direct viral killing of thymocytes in vivo.
J Virol
71:8245,
1997[Abstract]
28.
Withers-Ward E,
Amado R,
Koka P,
Jamieson B,
Kaplan A,
Chen ISY,
Zack J:
Transient renewal of thymopoiesis in HIV-infected human thymic implants following antiviral therapy.
Nat Med
3:1102,
1997[Medline]
[Order article via Infotrieve]
29.
Hellerstein MK,
McCune JM:
T cell turnover in HIV-1 disease.
Immunity
7:583,
1997[Medline]
[Order article via Infotrieve]
30.
Maciejewski JP,
Weichold FF,
Young NS:
HIV-1 suppression of hematopoiesis in vitro mediated by envelope glycoprotein and TNF-alpha.
J Immunol
153:4303,
1994[Abstract]
31.
Sandborg CI,
Imfeld KL,
Zaldivar FJ,
Berman MA:
HIV type 1 induction of interleukin 1 and 6 production by human thymic cells.
AIDS Res Hum Retroviruses
10:1221,
1994[Medline]
[Order article via Infotrieve]
32.
Schnittman SM,
Singer KH,
Greenhouse JJ,
Stanley SK,
Whichard LP,
Haynes BF,
Fauci AS:
Thymic microenvironment induces HIV expression. Physiologic secretion of IL-6 by thymic epithelial cells up-regulates virus expression in chronically infected cells.
J Immunol
147:2553,
1991
33.
Numazaki K,
Goldman H,
Bai XQ,
Wong I,
Wainberg MA:
Effects of infection by HIV-1, cytomegalovirus, and human measles virus on cultured human thymic epithelial cells.
Microbiol Immunol
33:733,
1989[Medline]
[Order article via Infotrieve]
34.
Numazaki K,
Bai QX,
Goldman H,
Wong I,
Spira B,
Wainberg MA:
Infection of cultured human thymic epithelial cells by human immunodeficiency virus.
Clin Immunol Immunopathol
51:185,
1989[Medline]
[Order article via Infotrieve]
35.
Bahner I,
Kearns K,
Coutinho S,
Leonard EH,
Kohn DB:
Infection of human marrow stroma by human immunodeficiency virus-1 (HIV-1) is both required and sufficient for HIV-1-induced hematopoietic suppression in vitro: Demonstration by gene modification of primary human stroma.
Blood
90:1787,
1997
36.
Zauli G,
Re MC,
Visani G,
Furlini G,
La Placa M:
Inhibitory effect of HIV-1 envelope glycoproteins gp120 and gp160 on the in vitro growth of enriched (CD34+) hematopoietic progenitor cells.
Arch Virol
122:271,
1992[Medline]
[Order article via Infotrieve]
37.
Mackall CL,
Fleisher TA,
Brown MR,
Wexler L,
Horowitz MA,
Magrath IT,
Shad AT,
Steinberg SA,
Chen CC,
Andrich MA,
Feuerstein I,
Gress RE:
Age, thymopoiesis and CD4+ T lymphocyte regeneration after intensive chemotherapy.
N Engl J Med
332:143,
1995
38. McCune JM, Loftus R, Schmidt DK, Carroll P, Webster D, Swor-Yim
LB, Francis IR, Gross BH, Grant RM: High prevalence of thymic tissue in
adults with HIV-1 infection. J Clin Invest (in press)
39.
Rabin RL,
Roederer M,
Maldonado Y,
Petru A,
Herzenberg LA,
Herzenberg LA:
Altered representation of naive and memory CD8 T cell subsets in HIV-infected children.
J Clin Invest
95:2054,
1995
40.
Roederer M,
Dubs JG,
Anderson MT,
Raju PA,
Herzenberg LA,
Herzenberg LA:
CD8 naive T cell counts decrease progressively in HIV-infected adults.
J Clin Invest
95:2061,
1995
41.
Ho DD,
Neumann AU,
Perelson AS,
Chen W,
Leonard JM,
Markowitz M:
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.
Nature
373:123,
1995[Medline]
[Order article via Infotrieve]
42.
Wolthers KC,
Bea G,
Wisman A,
Otto SA,
de Roda Husman AM,
Schaft N,
de Wolf K,
Goudsmit J,
Coutinho RA,
van der Zee AG,
Meyaard L,
Miedema F:
T cell telomere length in HIV-1 infection: No evidence for increased CD4+ T cell turnover.
Science
274:1543,
1996 This article has been cited by other articles:
| ||||||||||